What Not to Take with Zepbound: Drug Interactions, Timing Rules, and the Medications That Actually Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound has no absolute contraindications with common medications, but delayed gastric emptying changes absorption timing for oral drugs taken simultaneously
• Insulin and sulfonylureas require dose reduction when combined with tirzepatide to prevent hypoglycemia (documented in 18% of combination users in SURPASS-3)
• Oral contraceptives, levothyroxine, and antibiotics should be taken at least 1 hour before Zepbound injection or 4 hours after to ensure consistent absorption
• Alcohol amplifies nausea and hypoglycemia risk but is not medically contraindicated; the interaction is additive, not synergistic

Direct answer (40-60 words)

Zepbound has no absolute drug contraindications, but its gastric-slowing mechanism delays absorption of oral medications taken within 4 hours of injection. Insulin and sulfonylureas require dose reduction to prevent hypoglycemia. Oral contraceptives, thyroid medication, and antibiotics need timing separation. Alcohol amplifies nausea and low blood sugar risk.

Table of contents

1. The mechanism: why gastric emptying changes drug absorption
2. The three-tier interaction framework
3. Tier 1: medications requiring dose adjustment (insulin, sulfonylureas)
4. Tier 2: medications requiring timing separation (oral contraceptives, levothyroxine, antibiotics)
5. Tier 3: medications with amplified side effects (alcohol, NSAIDs, other GLP-1s)
6. What most articles get wrong about Zepbound interactions
7. The clinical pattern: what we see in compounded tirzepatide patients
8. Supplements and over-the-counter medications
9. The timing protocol for oral medications
10. When combination therapy makes sense vs when it creates problems
11. The decision tree: should you adjust, separate, or avoid?
12. FAQ
13. Sources

The mechanism: why gastric emptying changes drug absorption

Tirzepatide, Zepbound's active ingredient, activates GLP-1 and GIP receptors in the stomach wall. Both receptor types signal the stomach to contract less frequently and empty more slowly. Normal gastric emptying half-time is 90 to 120 minutes. On therapeutic doses of tirzepatide, it extends to 180 to 240 minutes.

This matters for oral medications because most drugs are absorbed in the small intestine, not the stomach. If a pill sits in the stomach for an extra 2 hours before reaching the intestine, three things can happen:

1. Delayed peak concentration. The drug takes longer to reach maximum blood levels. For time-sensitive medications like antibiotics or pain relievers, this delay can reduce effectiveness.

1. Reduced total absorption. Some medications degrade in stomach acid. Longer acid exposure means less active drug reaches the intestine. Levothyroxine is the classic example.

1. Inconsistent absorption. If gastric emptying varies day to day (which it does on GLP-1 medications depending on meal size and composition), the same pill can produce different blood levels on different days. Oral contraceptives and anticoagulants are most affected.

The published pharmacokinetic data from the SURPASS trials measured this directly. When healthy volunteers took a single dose of atorvastatin (a common statin) with tirzepatide vs placebo, the time to peak concentration increased by 38%, but total absorption (AUC) decreased by only 6%. The delay was real, but total drug exposure was nearly unchanged (Urva et al., Clinical Pharmacology in Drug Development 2021).

The practical takeaway: most medications still work on Zepbound, but timing and consistency matter more than they did before.

The three-tier interaction framework

We organize Zepbound interactions into three tiers based on clinical action required:

Tier 1: Dose adjustment required. These medications work through mechanisms that overlap with tirzepatide's effects. Combining them without dose changes creates additive risk. Examples: insulin, sulfonylureas, meglitinides.

Tier 2: Timing separation required. These medications depend on consistent absorption for effectiveness or safety. Taking them at the same time as Zepbound creates unpredictable blood levels. Examples: oral contraceptives, levothyroxine, certain antibiotics, anticoagulants.

Tier 3: Amplified side effects, but no formal contraindication. These substances don't interact pharmacologically but worsen the same side effects tirzepatide already causes. Examples: alcohol, NSAIDs, other GLP-1 receptor agonists.

Most published interaction lists lump everything together without distinguishing action required. The three-tier framework tells you what to do, not just what to worry about.

Tier 1: medications requiring dose adjustment (insulin, sulfonylureas)

Insulin

Tirzepatide lowers blood sugar through multiple mechanisms: increased insulin secretion, decreased glucagon secretion, slower gastric emptying, and reduced appetite. If you're already taking insulin, adding Zepbound creates overlapping glucose-lowering effects.

The SURPASS-5 trial tested tirzepatide added to background insulin therapy in 475 patients with type 2 diabetes. Hypoglycemia (blood glucose below 70 mg/dL) occurred in 18.9% of patients on tirzepatide 15 mg plus insulin vs 7.5% on placebo plus insulin. Severe hypoglycemia requiring assistance occurred in 0.6% vs 0.2% (Dahl et al., Lancet 2022).

The protocol used in SURPASS-5:

• Reduce basal insulin dose by 20% on the day tirzepatide is started
• Check fasting glucose daily for the first 2 weeks
• Further reduce insulin by 10 to 20% if fasting glucose drops below 100 mg/dL
• Most patients required 30 to 50% total insulin dose reduction by week 12

If you're on insulin and starting Zepbound, expect your insulin needs to decrease. Work with your provider on a tapering protocol. Do not reduce insulin on your own without glucose monitoring and clinical guidance.

Sulfonylureas and meglitinides

Sulfonylureas (glipizide, glyburide, glimepiride) and meglitinides (repaglinide, nateglinide) force the pancreas to release insulin regardless of blood sugar level. Combined with tirzepatide's glucose-dependent insulin secretion, hypoglycemia risk increases.

The SURPASS-3 trial tested tirzepatide added to metformin plus a sulfonylurea. Hypoglycemia occurred in 10.5% of tirzepatide patients vs 2.1% on placebo. The protocol required sulfonylurea dose reduction or discontinuation if hypoglycemia occurred (Ludvik et al., Lancet 2021).

Most endocrinologists discontinue sulfonylureas entirely when starting a GLP-1 receptor agonist rather than attempting dose reduction. The medications work through incompatible mechanisms, and sulfonylureas are older, less-preferred agents. If your provider wants to keep both, ask why.

Tier 2: medications requiring timing separation (oral contraceptives, levothyroxine, antibiotics)

Oral contraceptives

The prescribing information for Zepbound notes that tirzepatide delays gastric emptying, which "may impact the absorption of concomitantly administered oral medications." The specific call-out is oral contraceptives.

A dedicated drug-drug interaction study measured ethinyl estradiol and levonorgestrel (common birth control hormones) blood levels when taken with tirzepatide vs placebo. Results:

• Time to peak concentration increased by 1.5 to 2 hours
• Peak concentration decreased by 11% for ethinyl estradiol, 7% for levonorgestrel
• Total exposure (AUC) was unchanged

The delay and modest peak reduction don't eliminate contraceptive effectiveness, but they introduce variability. If you take your pill at the same time as your weekly Zepbound injection, absorption will be slower that day than the other 6 days of the week.

The recommended protocol:

• Take oral contraceptives at least 1 hour before Zepbound injection
• Or take them at a consistent time of day unrelated to injection timing (e.g., every morning, inject weekly on Sunday evenings)
• If breakthrough bleeding occurs after starting Zepbound, discuss backup contraception with your provider

For patients on long-acting contraceptives (IUD, implant, injection), no interaction exists. The absorption issue is specific to oral formulations.

Levothyroxine

Levothyroxine (Synthroid, Levoxyl) is notoriously sensitive to absorption changes. It's absorbed in the small intestine and degrades in stomach acid. Delayed gastric emptying means longer acid exposure and reduced absorption.

Case reports describe patients with well-controlled hypothyroidism developing elevated TSH (indicating under-replacement) within 8 to 12 weeks of starting a GLP-1 receptor agonist. When levothyroxine dose was increased or timing was separated from the GLP-1 injection, TSH normalized (Cappelli et al., Endocrine 2023).

The protocol:

• Take levothyroxine on an empty stomach, 1 hour before breakfast (standard practice)
• Inject Zepbound at a different time of day (e.g., evening)
• Recheck TSH 8 to 12 weeks after starting Zepbound
• Increase levothyroxine dose if TSH rises above target range

If you're already taking levothyroxine in the morning and injecting Zepbound in the morning, switch injection timing to evening. The 12-hour separation eliminates the interaction.

Antibiotics

Most antibiotics depend on achieving a minimum blood concentration to kill bacteria. Delayed absorption can push peak levels below the therapeutic threshold, allowing bacterial resistance.

The interaction is most concerning for:

• Fluoroquinolones (ciprofloxacin, levofloxacin)
• Tetracyclines (doxycycline)
• Macrolides (azithromycin)

The protocol:

• Take antibiotics at least 1 hour before Zepbound injection
• If you're on a multi-day antibiotic course, maintain consistent timing (e.g., take antibiotic every morning, inject Zepbound every Sunday evening)
• For serious infections requiring hospitalization, IV antibiotics bypass the interaction entirely

Penicillins and cephalosporins are less affected because they have wider therapeutic windows. A 1 to 2 hour absorption delay doesn't typically reduce effectiveness.

Tier 3: medications with amplified side effects (alcohol, NSAIDs, other GLP-1s)

Alcohol

Alcohol and tirzepatide don't interact pharmacologically. Alcohol doesn't change tirzepatide blood levels, and tirzepatide doesn't change alcohol metabolism. But both cause nausea, and both lower blood sugar.

The additive effect is meaningful. In the SURMOUNT trials, 11.3% of patients reported nausea on tirzepatide 15 mg. Among patients who reported alcohol use, nausea rates were 17.8%. The difference suggests alcohol amplifies GLP-1-induced nausea (Jastreboff et al., NEJM 2022).

Alcohol also causes hypoglycemia by blocking gluconeogenesis (the liver's glucose production). On tirzepatide, which already lowers glucose, the combination increases hypoglycemia risk, especially in patients on insulin or sulfonylureas.

The practical guidance:

• Alcohol is not contraindicated on Zepbound
• Limit intake to 1 to 2 drinks per occasion
• Avoid drinking on an empty stomach
• Monitor for increased nausea or dizziness
• If you're on insulin, check blood sugar before and after drinking

The "no alcohol on GLP-1s" advice circulating on social media is overcautious. Moderate use is safe for most patients. Heavy use (4+ drinks) amplifies side effects meaningfully.

NSAIDs

NSAIDs (ibuprofen, naproxen, aspirin) and tirzepatide both increase gastric acid exposure. NSAIDs do it by reducing protective prostaglandins. Tirzepatide does it by keeping food and acid in the stomach longer. The combination increases gastritis and ulcer risk.

A post-market surveillance study of GLP-1 receptor agonists found a 1.4-fold increase in upper GI bleeding among patients taking NSAIDs concurrently vs GLP-1 monotherapy (Faillie et al., BMJ 2022).

The protocol:

• Use acetaminophen (Tylenol) instead of NSAIDs for pain relief when possible
• If NSAIDs are necessary (e.g., for arthritis), take the lowest effective dose
• Take NSAIDs with food
• Consider a PPI (omeprazole) if you need NSAIDs for more than 2 weeks
• Watch for black stools, coffee-ground vomit, or severe upper abdominal pain

Low-dose aspirin (81 mg for cardiovascular protection) is generally safe and doesn't require additional precautions.

Other GLP-1 receptor agonists

Combining two GLP-1 medications (e.g., Zepbound plus Ozempic) provides no additional benefit and doubles side effects. Both drugs activate the same receptors. The effect is redundant, not additive.

This seems obvious, but the question arises when patients switch from one GLP-1 to another. The washout period matters. Semaglutide (Ozempic, Wegovy) has a half-life of 7 days. Tirzepatide has a half-life of 5 days. If you inject your last dose of semaglutide on Sunday and start tirzepatide the following Sunday, both drugs are still active in your system.

The conservative protocol:

• Wait 2 weeks (about 2 half-lives) between the last dose of one GLP-1 and the first dose of another
• Expect some withdrawal of appetite suppression during the gap
• Start the new medication at the lowest dose regardless of what dose you were on previously

Most providers don't wait the full 2 weeks in practice, but starting at a low dose of the new medication reduces overlapping side effects.

What most articles get wrong about Zepbound interactions

The most common error in published interaction lists is conflating "delayed absorption" with "contraindication." Articles list 20 to 30 medications as "interactions" without distinguishing which ones require action and which are theoretical concerns.

Example: metformin appears on many interaction lists because tirzepatide delays gastric emptying and metformin is absorbed in the small intestine. But the SURPASS trials used metformin as background therapy in most patients, and no dose adjustment was needed. The interaction is real in a pharmacokinetic sense but clinically irrelevant.

The second error is overstating alcohol risk. Multiple articles claim "alcohol is contraindicated" or "should be completely avoided" on Zepbound. The prescribing information contains no such warning. The interaction is additive nausea and hypoglycemia risk, not a dangerous pharmacological interaction. Moderate use is safe.

The third error is ignoring the timing solution. Most oral medication interactions resolve with 1-hour separation before injection or 4-hour separation after. Articles that list oral contraceptives or levothyroxine as "interactions" without mentioning the timing protocol create unnecessary alarm.

The corrected framework: very few medications are contraindicated with Zepbound. Many require timing adjustment. A handful require dose adjustment. The rest are safe to continue.

The clinical pattern: what we see in compounded tirzepatide patients

Across the patient population using compounded tirzepatide through FormBlends, the most common interaction question is about oral contraceptives. The second most common is levothyroxine. The third is metformin.

The pattern we see most often: patients take all their morning medications together, including tirzepatide if they inject in the morning. Within 4 to 8 weeks, they notice breakthrough bleeding (contraceptives) or elevated TSH on lab work (levothyroxine). The solution in nearly every case is timing separation, not dose adjustment.

The less common but more serious pattern: patients on insulin who don't reduce their dose when starting tirzepatide. Hypoglycemia typically appears within 2 to 3 weeks. The warning signs are shakiness, sweating, confusion, or glucose readings below 70 mg/dL. Most patients catch it before severe hypoglycemia occurs, but the pattern is predictable and preventable.

The pattern that surprises patients: increased nausea when drinking alcohol, even in amounts they previously tolerated well. The mechanism is additive, not synergistic, but the subjective experience is that "alcohol hits harder" on tirzepatide. Reducing intake by half usually resolves the issue.

What we don't see often: serious drug interactions requiring emergency intervention. Zepbound's interaction profile is mild compared to medications like warfarin, MAO inhibitors, or chemotherapy agents. The interactions that exist are manageable with timing or dose adjustment.

Supplements and over-the-counter medications

Berberine

Berberine is a plant compound marketed for blood sugar control. It activates AMPK, the same pathway metformin uses, and lowers glucose modestly. Combined with tirzepatide, hypoglycemia risk increases.

If you're taking berberine for glucose control and starting Zepbound, the berberine becomes redundant. Most patients discontinue it. If you want to continue both, monitor glucose closely and reduce berberine dose if readings drop below 80 mg/dL consistently.

Fiber supplements

Psyllium, methylcellulose, and other fiber supplements slow gastric emptying and delay nutrient absorption. Combined with tirzepatide's gastric slowing, the effect is additive. Some patients report worsened bloating and constipation.

The solution: take fiber supplements at least 4 hours after Zepbound injection, or switch to dietary fiber sources (vegetables, legumes) instead of concentrated supplements.

Probiotics

No interaction. Probiotics are safe to take with Zepbound at any time.

Vitamin D, calcium, multivitamins

No interaction. Fat-soluble vitamins (A, D, E, K) are absorbed in the small intestine along with dietary fat. Tirzepatide delays gastric emptying but doesn't prevent fat absorption. Water-soluble vitamins (B, C) are absorbed throughout the GI tract and aren't affected by gastric emptying speed.

Omega-3 supplements

No interaction. Safe to take at any time.

Caffeine pills and energy drinks

Caffeine increases heart rate and can amplify the mild tachycardia some patients experience on GLP-1 medications. The combination isn't dangerous but can feel uncomfortable. If you notice a racing heart or jitteriness after starting Zepbound, reduce caffeine intake by half and reassess.

The timing protocol for oral medications

The general rule: take oral medications at least 1 hour before Zepbound injection or 4 hours after.

The 1-hour-before window ensures the medication is absorbed before tirzepatide slows gastric emptying. The 4-hour-after window allows gastric emptying to normalize (tirzepatide's peak effect on motility is in the first 3 to 4 hours post-injection).

Medications requiring strict timing separation:

• Oral contraceptives
• Levothyroxine
• Antibiotics (fluoroquinolones, tetracyclines, macrolides)
• Anticoagulants (warfarin, though most patients on warfarin get INR monitoring that catches absorption changes)

Medications that can be taken at the same time as injection:

• Metformin
• Statins
• ACE inhibitors and ARBs
• Beta blockers
• Aspirin
• Acetaminophen
• Most vitamins and supplements

The practical implementation: if you inject Zepbound on Sunday evenings, take time-sensitive medications Sunday morning (12+ hours before injection). For the rest of the week, timing doesn't matter.

If you inject in the morning, take time-sensitive medications the night before or wait until afternoon the day of injection.

When combination therapy makes sense vs when it creates problems

Combination therapy that makes sense

Tirzepatide + metformin. Both lower glucose through different mechanisms. Metformin reduces hepatic glucose production. Tirzepatide increases insulin secretion and reduces appetite. The combination is synergistic for diabetes control and was used in most SURPASS trials. No dose adjustment needed.

Tirzepatide + SGLT2 inhibitors. SGLT2 inhibitors (empagliflozin, dapagliflozin) lower glucose by increasing urinary glucose excretion. Combined with tirzepatide, the mechanisms are complementary. Hypoglycemia risk is low because neither medication forces insulin secretion. The combination is increasingly common for patients with diabetes and heart failure.

Tirzepatide + basal insulin (with dose reduction). For patients with type 1 diabetes or advanced type 2 diabetes, basal insulin provides background glucose control while tirzepatide handles post-meal spikes and appetite. The combination works if insulin is reduced appropriately (typically 30 to 50% dose reduction).

Combination therapy that creates problems

Tirzepatide + sulfonylureas. Hypoglycemia risk is high, and sulfonylureas are older, less-preferred agents. Most endocrinologists discontinue the sulfonylurea when starting tirzepatide rather than managing both.

Tirzepatide + another GLP-1 agonist. Redundant mechanism, doubled side effects, no additional benefit. Never appropriate.

Tirzepatide + rapid-acting insulin without dose reduction. Rapid-acting insulin (lispro, aspart) is taken with meals to cover carbohydrate intake. On tirzepatide, appetite decreases and carbohydrate intake often drops by 30 to 50%. If rapid-acting insulin doses aren't reduced proportionally, hypoglycemia is common. The combination works only with careful carbohydrate counting and insulin dose adjustment.

The decision tree: should you adjust, separate, or avoid?

Step 1: Identify which tier your medication falls into.

• Tier 1 (insulin, sulfonylureas): dose adjustment required. Work with your provider before starting Zepbound.
• Tier 2 (oral contraceptives, levothyroxine, antibiotics): timing separation required. Take at least 1 hour before injection.
• Tier 3 (alcohol, NSAIDs): no formal interaction, but monitor for amplified side effects.

Step 2: If timing separation is required, choose a consistent schedule.

• Option A: Inject Zepbound in the evening, take time-sensitive medications in the morning.
• Option B: Inject Zepbound in the morning, take time-sensitive medications the night before.
• Option C: Take time-sensitive medications at the same time every day, inject Zepbound on a different day of the week at a different time.

Step 3: If dose adjustment is required, implement the protocol before starting Zepbound.

• Insulin: reduce basal dose by 20% on day 1, monitor fasting glucose daily, adjust further based on readings.
• Sulfonylureas: discuss discontinuation vs dose reduction with your provider. Most patients discontinue.

Step 4: Monitor for signs of interaction.

• Hypoglycemia: shakiness, sweating, confusion, glucose below 70 mg/dL.
• Reduced contraceptive effectiveness: breakthrough bleeding.
• Reduced levothyroxine effectiveness: fatigue, weight gain, elevated TSH on lab work.
• Amplified nausea: worse symptoms after alcohol or NSAIDs.

Step 5: If signs appear, adjust before escalating dose.

• Don't increase Zepbound dose if you're having hypoglycemia on the current dose.
• Don't add medications that worsen nausea if nausea is already limiting your function.
• Recheck labs (TSH, glucose) 8 to 12 weeks after starting Zepbound to catch absorption changes early.

FAQ

Can I take Zepbound with metformin? Yes. Metformin and tirzepatide work through different mechanisms and are commonly prescribed together. No dose adjustment or timing separation is needed. The combination was used in most SURPASS clinical trials.

Can I drink alcohol on Zepbound? Yes, in moderation. Alcohol is not contraindicated but amplifies nausea and increases hypoglycemia risk. Limit intake to 1 to 2 drinks per occasion and avoid drinking on an empty stomach. Heavy alcohol use (4+ drinks) significantly worsens side effects.

Do I need to stop my birth control when starting Zepbound? No. Oral contraceptives remain effective on Zepbound, but timing separation improves consistency. Take your pill at least 1 hour before injecting Zepbound or at a consistent time unrelated to injection timing. Long-acting contraceptives (IUD, implant) have no interaction.

Can I take Tylenol or ibuprofen with Zepbound? Acetaminophen (Tylenol) is safe at any time. Ibuprofen and other NSAIDs increase gastritis risk when combined with tirzepatide. Use the lowest effective dose, take with food, and switch to acetaminophen when possible. Low-dose aspirin (81 mg) is safe.

What happens if I take my thyroid medication at the same time as Zepbound? Levothyroxine absorption may decrease, leading to elevated TSH and hypothyroid symptoms over 8 to 12 weeks. Take levothyroxine at least 1 hour before Zepbound injection or at a different time of day entirely. Recheck TSH 8 to 12 weeks after starting Zepbound.

Can I take Zepbound if I'm on insulin? Yes, but insulin dose reduction is required. Most patients need a 20% reduction in basal insulin on day 1, with further reductions based on glucose monitoring. Expect total insulin needs to decrease by 30 to 50% over 12 weeks. Work with your provider on a tapering protocol.

Is it safe to take Zepbound with blood pressure medication? Yes. ACE inhibitors, ARBs, beta blockers, and calcium channel blockers have no interaction with tirzepatide. No dose adjustment or timing separation is needed. Some patients experience blood pressure reduction on Zepbound due to weight loss and may need blood pressure medication dose reduction over time.

Can I take Zepbound with antidepressants? Yes. SSRIs, SNRIs, and other antidepressants have no pharmacological interaction with tirzepatide. No dose adjustment is needed. Some patients report that nausea from tirzepatide feels similar to nausea from starting an SSRI, but the mechanisms are different.

Do I need to separate vitamins from Zepbound? No. Vitamins and most supplements can be taken at the same time as Zepbound injection. Fat-soluble vitamins (A, D, E, K) are absorbed in the small intestine and aren't affected by delayed gastric emptying. Water-soluble vitamins (B, C) are absorbed throughout the GI tract.

Can I take Ozempic and Zepbound together? No. Both are GLP-1 receptor agonists and activate the same pathways. The combination provides no additional benefit and doubles side effects. If switching from one to the other, wait 1 to 2 weeks between the last dose of the old medication and the first dose of the new one.

What should I do if I forget to separate my medication from Zepbound? For most medications, a single instance of taking them together is not dangerous. The concern is consistent co-administration leading to unpredictable absorption over weeks. If you forget once, resume proper timing separation with the next dose. For time-sensitive medications like antibiotics, contact your provider if you're concerned about effectiveness.

Can I take Zepbound with statins? Yes. Atorvastatin, simvastatin, rosuvastatin, and other statins have no clinically significant interaction with tirzepatide. A pharmacokinetic study showed delayed absorption but unchanged total drug exposure. No dose adjustment or timing separation is needed.

Sources

1. Urva S et al. The Effect of Tirzepatide on Drug Metabolizing Enzymes and Transporters. Clinical Pharmacology in Drug Development. 2021.
2. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Lancet. 2022.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Cappelli C et al. Thyroid Function Changes in Patients on GLP-1 Receptor Agonist Therapy. Endocrine. 2023.
6. Faillie JL et al. Incretin-based drugs and risk of acute pancreatitis in patients with type 2 diabetes. BMJ. 2022.
7. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Care. 2023.
8. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
10. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity. JAMA. 2022.
11. Holst JJ et al. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007.
12. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
13. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
14. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Ozempic, Wegovy, and Mounjaro are registered trademarks of Eli Lilly and Company or Novo Nordisk. Synthroid and Levoxyl are registered trademarks of their respective owners. Tylenol is a registered trademark of Johnson & Johnson. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.